Document is current
Any future updates will be listed below
-
Authors
Liu, Hengrui https://orcid.org/0000-0002-5214-1572
Zask, Arie
Forouhar, Farhad
Iketani, Sho https://orcid.org/0000-0002-3733-9556
Williams, Alana https://orcid.org/0000-0002-9380-0597
Vaz, Daniel R. https://orcid.org/0000-0003-4995-5724
Habashi, Dahlya
Choi, Karenna https://orcid.org/0000-0001-8678-240X
Resnick, Samuel J.
Hong, Seo Jung
Lovett, David H.
Bai, Tian
Chavez, Alejandro
Ho, David D. https://orcid.org/0000-0003-1627-149X
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
-
Funding
Funding for this research was provided by:
Columbia University
Columbia Technology Accelerator
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 10 December 2024
First Online: 2 January 2025
Competing interests
: S.I., H.L., A.Z., F.F., B.R.S., A.C., and D.D.H. are inventors on a patent application submitted based on this work. B.R.S. is an inventor on additional patents and patent applications related to small molecule therapeutics, and co-founded and serves as a consultant to Exarta Therapeutics, and ProJenX Inc., serves as a consultant to Weatherwax Biotechnologies and Akin Gump Strauss Hauer & Feld LLP, and holds equity in Sonata Therapeutics. S.I. and D.D.H. have sponsored research agreements with Enanta Pharmaceuticals, Shionogi & Co., Ltd., and Regeneron Pharmaceuticals. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics, Brii Biosciences, Apexigen, and Veru Inc., and board director for Vicarious Surgical. The remaining authors declare no competing interests.
